2023 MASCC 和 ESMO 指南更新：预防化疗和放疗引起的恶心和呕吐。
2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting.
机构信息
Department of Clinical Oncology, Zealand University Hospital Roskilde and Naestved, Roskilde; Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Oncology Supportive Care Consultant, Overland Park, USA.
出版信息
ESMO Open. 2024 Feb;9(2):102195. doi: 10.1016/j.esmoop.2023.102195. Epub 2024 Jan 11.
Abstract
• Nausea and vomiting are considered amongst the most troublesome adverse events for patients receiving antineoplastics. • The guideline covers emetic risk classification, prevention and management of treatment-induced nausea and vomiting. • The Consensus Committee consisted of 34 multidisciplinary, health care professionals and three patient advocates. • Recommendations are based on evidence-based data (level of evidence) and the authors’ collective expert opinion (grade). • All recommendations are for the first course of antineoplastic therapy; modifications may be needed in subsequent courses.
摘要
• 恶心和呕吐被认为是接受抗肿瘤治疗的患者最麻烦的不良反应之一。 • 该指南涵盖了致吐风险分类、预防和处理治疗引起的恶心和呕吐。 • 共识委员会由 34 名多学科医疗保健专业人员和 3 名患者权益倡导者组成。 • 建议基于基于证据的数据（证据水平）和作者的集体专家意见（等级）。 • 所有建议均适用于抗肿瘤治疗的第一疗程；后续疗程可能需要进行修改。
相似文献
1
2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting.2023 MASCC 和 ESMO 指南更新：预防化疗和放疗引起的恶心和呕吐。
ESMO Open. 2024 Feb;9(2):102195. doi: 10.1016/j.esmoop.2023.102195. Epub 2024 Jan 11.
2
Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.MASCC和ESMO预防化疗及放疗引起的恶心和呕吐指南更新：佩鲁贾共识会议结果
Ann Oncol. 2010 May;21 Suppl 5:v232-43. doi: 10.1093/annonc/mdq194.
3
Going beyond the 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting.超越2023年MASCC和ESMO预防化疗和放疗引起的恶心和呕吐的指南更新。
Eur J Cancer. 2025 Jun 3;222:115451. doi: 10.1016/j.ejca.2025.115451. Epub 2025 Apr 19.
4
Practice Patterns for Prevention of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Adherence Based on Real-World Prescribing Data.基于真实世界处方数据的化疗所致恶心和呕吐预防及止吐药指南遵循的实践模式。
Oncologist. 2021 Jun;26(6):e1073-e1082. doi: 10.1002/onco.13716. Epub 2021 Mar 17.
5
2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.2016年更新的MASCC/ESMO共识建议：多日化疗、大剂量化疗后恶心和呕吐的预防以及突破性恶心和呕吐。
Support Care Cancer. 2017 Jan;25(1):303-308. doi: 10.1007/s00520-016-3449-y. Epub 2016 Nov 4.
6
2023 Updated MASCC/ESMO Consensus Recommendations: prevention of radiotherapy- and chemoradiotherapy-induced nausea and vomiting.2023 年更新的 MASCC/ESMO 共识推荐意见：预防放疗和放化疗引起的恶心和呕吐。
Support Care Cancer. 2023 Dec 15;32(1):26. doi: 10.1007/s00520-023-08226-z.
7
2016 updated MASCC/ESMO consensus recommendations: prevention of radiotherapy-induced nausea and vomiting.2016年更新的MASCC/ESMO共识建议：预防放疗引起的恶心和呕吐。
Support Care Cancer. 2017 Jan;25(1):309-316. doi: 10.1007/s00520-016-3407-8. Epub 2016 Sep 13.
8
MASCC antiemetic consensus recommendations: resource-limited settings.MASCC 止吐共识建议：资源有限的环境
Support Care Cancer. 2025 Feb 12;33(3):181. doi: 10.1007/s00520-025-09211-4.
9
2016 Updated MASCC/ESMO Consensus Recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potential.2016年更新的MASCC/ESMO共识建议：控制低致吐或极低致吐风险化疗引起的恶心和呕吐
Support Care Cancer. 2017 Jan;25(1):297-301. doi: 10.1007/s00520-016-3391-z. Epub 2016 Aug 30.
10
Radiotherapy-induced nausea and vomiting (RINV): MASCC/ESMO guideline for antiemetics in radiotherapy: update 2009.放疗所致恶心呕吐（RINV）：MASCC/ESMO 放疗止吐治疗指南：2009 年更新。
Support Care Cancer. 2011 Mar;19 Suppl 1:S5-14. doi: 10.1007/s00520-010-0950-6. Epub 2010 Aug 10.
引用本文的文献
1
Pharmacokinetics, safety, and efficacy of mixed formulation of fosrolapitant and palonosetron (HR20013) in combination with dexamethasone in patients with solid tumors scheduled for highly emetogenic cisplatin-based chemotherapy: a phase I trial.磷丙泊酚和帕洛诺司琼混合制剂（HR20013）联合地塞米松用于计划接受高致吐性顺铂化疗的实体瘤患者的药代动力学、安全性及疗效：一项I期试验
BMC Med. 2025 Aug 27;23(1):501. doi: 10.1186/s12916-025-04314-5.
2
Efficacy of intensive antiemetic therapy including olanzapine in multiple myeloma patients treated with high-dose melphalan with autologous stem cell transplantation.在接受大剂量美法仑联合自体干细胞移植治疗的多发性骨髓瘤患者中，包括奥氮平在内的强化止吐疗法的疗效。
Support Care Cancer. 2025 Aug 11;33(9):777. doi: 10.1007/s00520-025-09839-2.
3
Individual patient data meta-analysis of NEPA versus aprepitant-based antiemetic regimens for preventing chemotherapy-induced nausea and vomiting.奈妥匹坦与基于阿瑞匹坦的止吐方案预防化疗引起的恶心和呕吐的个体患者数据荟萃分析。
Future Oncol. 2025 Sep;21(21):2823-2833. doi: 10.1080/14796694.2025.2542108. Epub 2025 Aug 9.
4
GDF15 and history of pregnancy-induced nausea as predictors of treatment-induced nausea severity in women following surgery for early-stage breast cancer.生长分化因子15及妊娠剧吐史作为早期乳腺癌术后女性治疗引起的恶心严重程度的预测指标
Support Care Cancer. 2025 Jul 23;33(8):714. doi: 10.1007/s00520-025-09769-z.
5
Management of trastuzumab deruxtecan-related adverse events in breast cancer: Italian expert panel recommendations.乳腺癌中曲妥珠单抗德曲妥珠单抗相关不良事件的管理：意大利专家小组建议
Future Oncol. 2025 Aug;21(20):2565-2573. doi: 10.1080/14796694.2025.2535171. Epub 2025 Jul 23.
6
Impact of antiemetic steroid use on survival in small cell lung cancer patients receiving immune checkpoint inhibitors and chemotherapy.使用止吐类固醇对接受免疫检查点抑制剂和化疗的小细胞肺癌患者生存的影响。
Sci Rep. 2025 Jul 1;15(1):22108. doi: 10.1038/s41598-025-05899-w.
7
Practical Management of Zolbetuximab Administration: The Project VYLOY Initiative.佐贝妥昔单抗给药的实际管理：VYLOY项目倡议
Cancers (Basel). 2025 Jun 15;17(12):1996. doi: 10.3390/cancers17121996.
8
Incidence and Risk Factors of Platinum-Based Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Meta-Analysis.铂类化疗所致恶心和呕吐的发生率及危险因素：一项系统评价和Meta分析
Curr Oncol. 2025 May 31;32(6):325. doi: 10.3390/curroncol32060325.
9
Exploring antiemetic strategies in hematologic malignancies: a comprehensive literature review and evaluation of antiemetic efficacy in patients receiving high-dose chemotherapy prior to hematopoietic stem cell transplantation.探索血液系统恶性肿瘤的止吐策略：一项关于造血干细胞移植前接受大剂量化疗患者止吐疗效的综合文献综述与评估
Support Care Cancer. 2025 Jun 24;33(7):622. doi: 10.1007/s00520-025-09638-9.
10
Meta-analysis of compression therapy for prevention of chemotherapy-induced peripheral neuropathy.预防化疗引起的周围神经病变的加压疗法的荟萃分析。
Support Care Cancer. 2025 Jun 6;33(7):549. doi: 10.1007/s00520-025-09589-1.
本文引用的文献
1
Effect of a Standardized Ginger Root Powder Regimen on Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Double-Blind, Placebo-Controlled Randomized Trial.标准化姜根粉方案对化疗引起的恶心和呕吐的影响：一项多中心、双盲、安慰剂对照随机试验。
J Acad Nutr Diet. 2024 Mar;124(3):313-330.e6. doi: 10.1016/j.jand.2023.09.003. Epub 2023 Sep 10.
2
Effects of food-based interventions in the management of chemoradiotherapy-induced nausea and vomiting: a systematic review.基于食物的干预措施在管理放化疗引起的恶心和呕吐中的作用：系统评价。
Support Care Cancer. 2023 Jun 23;31(7):413. doi: 10.1007/s00520-023-07879-0.
3
A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study).一项关于奥氮平联合三联止吐方案预防多日高致吐性化疗引起的恶心和呕吐的多中心、随机、双盲、安慰剂对照3期试验（OFFER研究）。
EClinicalMedicine. 2022 Dec 15;55:101771. doi: 10.1016/j.eclinm.2022.101771. eCollection 2023 Jan.
4
Challenges in the Development of Intravenous Neurokinin-1 Receptor Antagonists: Results of a Safety and Pharmacokinetics Dose-Finding, Phase 1 Study of Intravenous Fosnetupitant.静脉注射神经激肽-1 受体拮抗剂研发面临的挑战：福沙那肽静脉注射的安全性和药代动力学剂量确定、I 期研究结果。
Clin Pharmacol Drug Dev. 2022 Dec;11(12):1405-1418. doi: 10.1002/cpdd.1183. Epub 2022 Oct 20.
5
Dietary strategies for chemotherapy-induced nausea and vomiting: A systematic review.化疗所致恶心呕吐的饮食策略：系统评价。
Clin Nutr. 2022 Oct;41(10):2147-2155. doi: 10.1016/j.clnu.2022.08.003. Epub 2022 Aug 17.
6
Efficacy of Olanzapine 5 mg versus 10 mg for the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving High Emetic Risk Chemotherapy without Neurokinin-1 Receptor Antagonist.奥氮平 5 毫克与 10 毫克预防未使用神经激肽-1 受体拮抗剂的高致吐风险化疗药物所致恶心呕吐的疗效比较。
Asian Pac J Cancer Prev. 2022 Jun 1;23(6):2137-2143. doi: 10.31557/APJCP.2022.23.6.2137.
7
Aprepitant plus palonosetron versus dexamethasone plus palonosetron in preventing chemotherapy-induced nausea and vomiting in patients with moderate-emetogenic chemotherapy: A randomized, open-label, phase 3 trial.阿瑞匹坦联合帕洛诺司琼与地塞米松联合帕洛诺司琼预防中度致吐性化疗患者化疗引起的恶心和呕吐：一项随机、开放标签的3期试验。
EClinicalMedicine. 2022 Jun 3;49:101480. doi: 10.1016/j.eclinm.2022.101480. eCollection 2022 Jul.
8
Multiple-day administration of fosaprepitant combined with tropisetron and olanzapine improves the prevention of nausea and vomiting in patients receiving chemotherapy prior to autologous hematopoietic stem cell transplant: a retrospective study.多日给予福沙匹坦联合托烷司琼和奥氮平可改善接受自体造血干细胞移植前化疗患者的止吐效果：一项回顾性研究。
Ann Hematol. 2022 Aug;101(8):1835-1841. doi: 10.1007/s00277-022-04877-w. Epub 2022 Jun 6.
9
A real-world study to evaluate the safety and efficacy of three injectable neurokinin-1 receptor antagonist formulations for the prevention of chemotherapy-induced nausea and vomiting in cancer patients.一项真实世界研究评估三种注射用神经激肽-1 受体拮抗剂制剂预防癌症患者化疗所致恶心呕吐的安全性和疗效。
Support Care Cancer. 2022 Aug;30(8):6649-6658. doi: 10.1007/s00520-022-07082-7. Epub 2022 May 2.
10
Olanzapine (5 mg) plus standard triple antiemetic therapy for the prevention of multiple-day cisplatin hemotherapy-induced nausea and vomiting: a prospective randomized controlled study.奥氮平（5 毫克）联合标准三联止吐疗法预防多日顺铂化疗引起的恶心和呕吐：一项前瞻性随机对照研究。
Support Care Cancer. 2022 Jul;30(7):6225-6232. doi: 10.1007/s00520-022-07067-6. Epub 2022 Apr 21.
Zotero 插件